



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM


MARK B. WILSON
PARTNER
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3035
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

July 15, 2004

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

July 15, 2004
Date  Mark B. Wilson

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/781,055 entitled "RATIONALLY DESIGNED AND CHEMICALLY SYNTHESIZED PROMOTER FOR GENETIC VACCINE AND GENE THERAPY" – Stephen Johnston and Bao-Xi Qu*
Our reference: UTSD:788US
Client reference: UTSD0788


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references A1-A3 and C1-C27.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSD:788US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Mark B. Wilson
Reg. No. 37,259

MBW/kmv
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Stephen Johnston
Bao-Xi Qu

Serial No.: 10/781,055


Filed: February 18, 2004

For: **RATIONALLY DESIGNED AND
CHEMICALLY SYNTHESIZED
PROMOTER FOR GENETIC VACCINE
AND GENE THERAPY**

Group Art Unit: 1653

Examiner: Unknown

Atty. Dkt. No.: UTSD:788US

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.	
July 15, 2004	
Date	Mark B. Wilson

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be


25432900.1

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSD:788US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson

Reg. No. 37,259

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: July 15, 2004

Form PTO-1449 (modified)

Atty. Docket No.

UTSD:788US

Serial No.

10/781,055

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Stephen Johnston

Bao-Xi Qu

Filing Date:

February 18, 2004

Group:

1653

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,683,202	7/28/87	Mullis	435	91	10/25/85
	A2	5,928,906	7/27/99	Köster <i>et al.</i>	435	91.2	5/09/96
	A3	6,410,210	6/25/02	Gabriel	430	315	5/30/99

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Barry <i>et al.</i> , "Protection against mycoplasma infection using expression-library immunization," <i>Nature</i> , 377(6550):632-635, 1995.
	C2	Breathnach and Chambon, "Organization and expression of eucaryotic split genes coding for proteins," <i>Annu. Rev. Biochem.</i> , 50:349-383, 1981.
	C3	Burke <i>et al.</i> , "The DPE, a conserved downstream core promoter element that is functionally analogous to the TATA box," <i>Cold Harbor Symposia on Quantitative Biology</i> , Volume LXIII, 75-82, The Mechanisms of Transcription, 1998.
	C4	Faisst and Meyer, "Compilation of vertebrate-encoded transcription factors," <i>Nucleic Acids Research</i> , 20(1):3-26, 1992.
	C5	Fujita <i>et al.</i> , "Delimitation and properties of DNA sequences required for the regulated expression of human interferon- β gene," <i>Cell</i> , 41(2):489-496, 1985.
	C6	Fynan <i>et al.</i> , "DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations," <i>Proc. Natl. Acad. Sci., USA</i> , 90:11478-11482, 1995.
	C7	Graves <i>et al.</i> , "Homologous recognition of a promoter domain common to the MSV LTR and the HSV tk gene," <i>Cell</i> , 44(4):565-576, 1986.

25397630.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

UTSD:788US

Serial No.

10/781,055

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Stephen Johnston

Bao-Xi Qu

Filing Date:

February 18, 2004

Group:

1653

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C8	Gronostajski, "Site-specific DNA binding of nuclear factor I: effect of the spacer region," <i>Nucleic Acids Research</i> , 15(14):5545-5559, 1987.
	C9	Harms and Splitter, "Interferon- γ inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter," <i>Hum. Gene Ther.</i> , 6(10):1291-1297, 1995.
	C10	Hu <i>et al.</i> , "Transcriptional factor AP-4 contains multiple dimerization domains that regulate dimer specificity," <i>Genes Dev.</i> , 4(10):1741-1752, 1990.
	C11	Kadonaga <i>et al.</i> , "Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain," <i>Cell</i> , 51(6):1079-1090, 1987.
	C12	Liu and Green, "A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus Ela protein," <i>Cell</i> , 61(7):1217-1224, 1990.
	C13	McDonnell and Askari, "Molecular medicine," <i>New Engl. J. Med.</i> , 334(1):42-45, 1996.
	C14	Mitchell and Tijian, "Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins," <i>Science</i> , 245(4916):371-378, 1989.
	C15	Pardoll <i>et al.</i> , "Exposing the immunology of naked DNA vaccines," <i>Immunity</i> , 3:165-169, 1995.
	C16	Perlmann <i>et al.</i> , "Determinants for selective RAR and TR recognition of direct repeat HREs," <i>Genes Dev.</i> , 7B:1411-1422, 1993.
	C17	Pollock <i>et al.</i> , "Human SRF-related proteins: DNA-binding properties and potential regulatory targets," <i>Genes Dev.</i> , 5(12A):2327-2341, 1991.
	C18	Qin <i>et al.</i> , "Promoter attenuation in gene therapy: interferon- γ and tumor necrosis factor- α inhibit transgene expression," <i>Hum. Gene Ther.</i> , 8(17):2019-2029, 1997.
	C19	Ritter <i>et al.</i> , "Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells," <i>Cytokine</i> , 12(8):1163-1170, 2000.
	C20	Robinson, "DNA based vaccines: new possibilities for disease prevention and treatment," <i>Can. Med. Assoc. J.</i> , 152(10):1629-1632, 1995.
	C21	Ruvkun and Finney, "Regulation of transcriptional and cell identity by POU domain proteins," <i>Cell</i> , 64(3):475-478, 1991.

25397630.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

UTSD:788US

Serial No.

10/781,055

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Stephen Johnston

Bao-Xi Qu

Filing Date:

February 18, 2004

Group:

1653

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C22	Smale and Baltimore, "The 'initiator' as a transcription control element," <i>Cell</i> , 57(1):103-113, 1989.
	C23	Spooner <i>et al.</i> , "DNA vaccination for cancer treatment," <i>Gene Therapy</i> , 2:173-180, 1995.
	C24	Tanaka <i>et al.</i> , "Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system," <i>Mol. Cell. Biol.</i> , 13(8):4531-4538, 1993.
	C25	Virbasius, "NRF-1, an activator involved in nuclear-mitochondrial interactions, utilizes a new DNA-binding domain conserved in a family of developmental regulators," <i>Genes Dev.</i> , 7(12A):2431-2445, 1992.
	C26	Williams and Tijian, "Analysis of the DNA-binding and activation properties of the human transcription factor AP-2," <i>Genes Dev.</i> , 5(4):670-682, 1991
	C27	Yen <i>et al.</i> , "An alternative spliced form of FosB is a negative regulator of transcriptional activation and transformation by Fos proteins," <i>Proc. Natl. Acad. Sci., USA</i> , 88(12):5077-5081, 1991.

25397630.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.